invest !!! One thing over the years I have developed is patience.... I'm just accumulating at these prices, this to me is just a gift. Once the 10q comes out with earnings, and any news on the trials,the .60's are long gone history. imho
MIV Therapeutics Names Methodist Hospital Research Cardiologist Dr. Greg Kaluza to Scientific Advisory Board 4:01p ET June 11, 2007 (Business Wire) MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that Dr. Greg L. Kaluza, M.D., Ph.D, a widely recognized expert in the field of interventional cardiology, has joined the company's Scientific Advisory Board, where he will help guide the company's clinical trials and other key research programs.
Dr. Kaluza is the F.A.C.C. Scientific Director at the Center for Research in Cardiovascular Interventions (CRCI) at the Methodist Hospital Research Institute in Houston, Texas. The CRCI is a multifaceted, highly specialized group focused on research in interventional cardiology. The CRCI houses an experimental animal laboratory, a cardiovascular angiographic analysis core, and a clinical research department.
"We believe that Dr. Kaluza's extensive experience and expertise will play a key roll in the development of our next generation cardiovascular stents," said Mark Landy, President of MIV Therapeutics. "We are very pleased to welcome him and feel honored to have him as a key member of our Advisory Board."
MIVT is developing a next-generation cardiovascular stent technology being designed to provide substantial health and safety benefits and outcomes over previous generations of drug-eluding stents. MIVT has developed a new line of both ultra-thin and drug-carrying cardiovascular stent coatings based on its proprietary hydroxyapatite (HAp) technology.
"I am looking forward to advising MIVT during this exciting period of growth for the Company as it moves its proprietary technologies from the laboratory to the marketplace," said Dr. Kaluza. "I believe that the industry is ready for the type of biocompatible stent coatings that MIVT is developing."
Dr. Kaluza has been published well over sixty times, including many engagements as a world recognized public speaker at major scientific symposiums. He has also been quoted in several manuscripts in International medical journals, on subjects such as prevention of restenosis in porcine model of balloon/stent injury with intra-coronary radiation and drug-eluting stents, development of bioresorbable stents, biocompatibility testing of medical device coatings, utility of intravascular ultrasound in predicting histologic outcomes in animal models of restenosis and atherosclerosis, as well as evaluation of Optical Coherence Tomography as a tool to monitor arterial responses to stenting and resorption of bioresorbable stents.
The role of the Scientific Advisory Board is to review and advise the Company's management and Board of Directors on scientific strategies and procedures and to provide input and critique on the Company's Research and Development activities.
About The Methodist Hospital Research Institute
The Methodist Hospital Research Institute in Houston, TX, is a cornerstone of The Methodist Hospital's strategic vision for its future as a top-ranked academic medical center. The Research Institute is committed to moving the latest discoveries in the laboratory to the bedside in order to provide a new standard of care for our patients in Houston and in other parts of the country. For more information on The Methodist Hospital and the Methodist Hospital Research Institute, see http://www.methodisthealth.com/.
About MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. MIVT's intellectual property portfolio includes patents held by the University of British Columbia (UBC). MIVT has worldwide exclusive rights to the technologies licensed from UBC. Key patent applications filed simultaneously in various countries around the world, further protect the commercial exclusivity of MIVT's own inventions in the global marketplace
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
SOURCE: MIV Therapeutics
MIV Therapeutics Inc. Investor Relations Anthony Huston, 604-301-9545, x14 Toll-free: 800-221-5108 Fax: 604-301-9546 investor@mivtherapeutics.com http://www.mivtherapeutics.com/ or Trilogy Capital Partners Financial Communications Ryon Harms, Toll-free: 800-592-6067 ryon@trilogy-capital.com
Market Data 
Markets 
AI
